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immunotherapy is the treatment of choice; 
in muscle-invasive disease, cystectomy is the 
most appropriate curative option [4].
Non-muscle-invasive bladder cancer (NMIBC) 
can be divided into three groups. The first group 
consists of a minority of patients (20-30%) who 
have a relatively benign type of transitional cell 
carcinoma (TCC) with a low recurrence rate. 
These low-risk tumors do not show progres-
sion. The second and largest group consists of 
patients who frequently develop a non-muscle-
invasive recurrence but seldom experience 
progression. The third, small group consists of 
patients who have a relatively aggressive non-
muscle-invasive tumor at presentation; despite 
maximum treatment, up to 45% of these pa-
tients will develop muscle-invasive cancer [5].
Although recurring well and moderately dif-
ferentiated NMIBC rarely progresses to a 
INTRODUCTION
Bladder cancer is the fourth most common 
malignancy among men in the Western world 
(after prostate, lung, and colon cancers) [1] 
and accounts for approximately 5–10% of 
all cancers in Europe and the United States 
[2]. The incidence of bladder cancer increases 
with age [2] and is up to 3-fold more common 
in men than in women [3]. In general, bladder 
cancer is confined to one of two categories: 
noninvasive (Ta, Tis, T1) or invasive (T2-T4).
Up to 85% of patients with bladder cancer 
presents with disease confined to the mucosa 
(stage Ta and Tis) or submucosa (stage T1). 
These non-muscle-invasive tumors are trea-
ted totally differently from muscle-invasive 
ones. In non-muscle-invasive disease, tran-
surethral resection of bladder (TURB) paired 
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ABSTRACT
BACKGROUND: Bladder cancer accounts for 5-10% of all cancers in Europe and up to 85% patients presents a nonin-
vasive tumor, whose treatment of choice is the transurethral bladder resection (TURB) paired with adjuvant intravesical 
chemotherapy or immunotherapy. Despite several clinical trials showed that this treatment is safe and decreases recurrences 
by 17% to 44% this practice is limited for many reasons. The study objective is to analyze the economical advantages of 
the single immediate post operative Mitomycin C instillation in Non Muscle-invasive Bladder Cancer (NMIBC) low-risk 
patients.
METHODS: A cost-benefit analysis was performed evaluating the economical gain that would raised from a scenario with 
a single immediate post operative mitomycin C instillation in each low-risk NMIBC patient who underwent to TURB. Net 
present value and cost-benefit ratio were calculated and sensitivity analyses were performed. Base case analysis was perfor-
med considering tumor recurrence rate reduction of 11.7% and a TURB costs of 2,167.0 €, while sensitivity analyses were 
performed using a recurrence rate reduction of 19.2% and 15.0% and a TURB cost of 2,472.93 €. The discount rate was 2%.
RESULTS: The single immediate post operative instillation of mitomycin C resulted to be cost-beneficial with a cost-bene-
fit ratio that goes from 0.48 to 0.79 when compared to TURB alone raising a Net Present Value that goes from 660,284.39 
€ to 2,650,530.79 €.
CONCLUSION: This study demonstrates that even assuming conservative parameters for recurrence rates reduction, a 
single immediate post operative mitomycin C instillation in low risk NMIBC patients would lower not only the recurrence 
rate but also the caring cost for bladder cancer. 
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life-threatening condition, repeated TURBs 
and courses of intravesical instillations of 
immuno- and chemotherapeutic agents cau-
se considerable inconvenience, expense, and 
morbidity. A single instillation of chemothe-
rapy immediately after TURB has been pro-
posed as a means of reducing recurrence by 
decreasing procedure-facilitated tumor im-
plantation and eradicating field effect or per-
sistent (incompletely resected or unrecogni-
zed) tumors [6-8]. For over a decade, several 
prospective randomized-controlled clinical 
trials (RCT) have shown that this treatment 
is safe and decreases recurrences by 17% to 
44% compared with controls [9-11], particu-
larly for patients with newly diagnosed blad-
der cancers [6-8; 12-14].
Despite the evidences, clinicians give pa-
tients a single immediate post operative che-
motherapy instillation in a limited number 
of cases. Madeb et al. aiming at evaluating 
whether US urologists have adopted this 
practice and its potential effect on costs 
of bladder cancer, found out that between 
1997 and 2004, among 16,748 patients with 
newly diagnosed bladder cancer, of whom 
14,677 underwent cystoscopic biopsy or 
TURB, only 49 (0.33%) received same-
day intravesical instillation of chemothe-
rapy. Nevertheless the authors conclude that 
adopting same-day intravesical instillation 
of chemotherapy in newly diagnosed low-
risk NMIBC patients who undergone to 
TURB, would significantly lower the cost of 
BC care [15].
The objective of the present study is to 
analyze the advantages of the single imme-
diate post operative chemotherapy instil-
lation in NMIBC low-risk patients from an 
economical point of view and focusing on 
mitomycin C (MMC) in Italy.
MATERIAL AND METHODS
Cost-benefit analysis (CBA), sometimes cal-
led benefit-cost analysis (BCA), is a syste-
matic process for calculating and comparing 
benefits and costs of a project, decision or 
government policy. CBA has two purposes: 
to determine if it is a sound investment/deci-
sion (justification/feasibility), and to provide 
a basis for comparing projects. It involves 
comparing the total expected cost of each op-
tion against the total expected benefits, to see 
whether the benefits outweigh the costs, and 
by how much.
For CBA, the most important calculation is 
the Net Present Value (NPV). NPV can give 
the clearest answer to whether a project re-
presents a sound investment and it is defined 
as the difference between the present value 
of cash inflows and the present value of cash 
outflows. When NPV is greater than zero it 
means that the discounted value of future cash 
flows is greater than the initial investment.
NPV formula is:
Where Bt represents each year’s benefits, t in-
dicates the year from 1 to T (the last year of 
the analysis), while Ct represents each year’s 
costs and r is the discount rate.
An alternative calculation that may be used to 
supplement the NPV calculation is the cost-
benefit ratio (CBR), calculated by taking the 
NPV of the costs and dividing it by the NPV 
of benefits. A CBR lower than one suggests 
that the strategy is acceptable since the NPV 
of benefits is greater than NPV of costs.
CBR formula is:
A cost-benefit analysis has been performed 
evaluating the potential economical gain that 
would be raised by an hypothetical scenario 
in which a single immediate post operative 
mitomycin C instillation is administered in 
each low-risk NMIBC patients who has un-
dergone to TURB in Italy.
Discounting is another procedure widely ap-
plied in these kind of analysis. It is defined as 
a procedure used in economic analysis to ex-
press as “present values” those costs and be-
nefits that will occur in future years. Pharma-
coeconomics uses discounting to account for 
the time preference associated with money 
in its methodology. Due to the benefits and 
returns that can be gained in the interim, indi-
viduals prefer to receive money sooner rather 
than later. For the same reason, we prefer to 
pay out money at some later date rather than 
today. In other words, money today is worth 
more than tomorrow. In our analysis we have 
applied a discount rate of 2% according with 
Banca d’Italia [16].
Study population
In Italy, in 2010 there have been around 
50,000 TURB [17]. Assuming that patients 
in the low-risk category are newly diagno-
sed and considering that low-risk patients are 
the 20-30% (25%) of total cases of NMIBC 
[5], it can be assumed that the total number 
of low-risk NMIBC patients who underwent 
TURB is 12,500, that is our study population.
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for a single mitomycin C instillation. As the 
expenditure is done during the first year, no 
discount rates have been applied to costs.
Benefits
In cost-benefits analysis, benefits are those 
costs that could be saved implementing the 
study strategy, that is the single post-operati-
ve MMC instillation. In this case, prevented 
costs are generated by patients that would ex-
perience a recurrence in case they have not 
been treated with MMC. These costs are tho-
se related to TURB, since the Italian National 
Health Service perspective has been chosen; 
the hospitalization reimbursements (DRG – 
Diagnosis Related Groups System) related to 
TURB surgeries have been considered. The 
mean cost associated to DRG 311 (transu-
rethral procedures without complications) 
considering all the regional pricelists in 2009 
is of 2,167.00 € [21]. A sensitivity analysis 
has been done using TURB cost reported by 
Racioppi et al. [19].
RESULTS
Cost-benefit analysis
The NPV of costs is given by the costs rela-
ted to MMC instillation in all patients who 
underwent TURB in one year.
As the expenditure is done during the first 
year, there are no costs to be applied for the 
Scenario
The aim of the present study is to evaluate 
whether a single immediate post operative 
intravesical instillation of mitomycin C in all 
newly diagnosed low-risk NMIBC patients 
would be cost savings when compared with 
TURB alone from the perspective of the Ita-
lian National Health Service considering a 3 
years period.
Parameters
A meta-analysis of the published results of 7 
randomized clinical trials comparing TURB 
alone to TURB plus 1 immediate instillation 
of chemotherapy has been performed by Syl-
vester et al. [18]. The study, that included 
1,476 patients who tended to be at low risk 
for recurrence as 89.2% had primary tumors, 
84.3% single tumors, 67.9% Ta disease and 
9.5% G3 disease, has shown a reduction of 
11.7% in the recurrence rate during a median 
follow-up of 3.4 years when administering a 
single chemotherapy instillation after TURB.
11.7% reduction in recurrence rate has been 
used for the base case scenario cost-benefit 
analysis. A sensitivity analysis has been per-
formed using the percentage of reduction in 
recurrence rate found by Tolley et al. [11] in 
a multicentre randomized clinical study per-
formed in 1996 where the differences in re-
currence rates was 19.2% on a 7 years fol-
low-up comparing low risk patients who 
underwent TURB + MMC against low-risk 
patients who underwent TURB alone, even if 
no distinctions have been done between pa-
tients with 1 MMC instillation and those with 
5 MMC instillations. It has been decided to 
adopt the percentage value from Sylvester et 
al. for the base case scenario since it comes 
from a meta-analysis of 7 clinical studies and 
it has also been taken has a reference by 
EORTC (European Organization for Rese-
arch and Treatment of Cancer). Another sen-
sitivity analysis has been done using a per-
centage of recurrence reduction that is the 
mean value between those ones reported by 
Sylvester and Tolley (Table I).
Costs
In cost-benefit analysis, costs are those gene-
rated by the implementation of the new stra-
tegy; in this case costs are generated by the 
single MMC instillation.
The cost of one instillation of mitomycin C 
has been reported to be of 177.30 € [19] and 
it includes the cost of the drug acquisition, 
the costs of medical and non medical person-
nel and those of other medications and mate-
rial used. Since this cost is referred to 2006, 
we have used ISTAT coefficient (1.103) [20] 
to update it to 2011 getting a 195.56 € value 
Parameters Value Data Source
Reference 
population
12,500 Adapted from Rapporto sull’attività di 
Ricovero Ospedaliero. Dati SDO 2010 
Ministero della Sanità, 2012 [17]
Reduction in recurrence rate
Base case 11.7% Sylvester et al. [18]
Sensitivity analysis 19.2% Tolley et al. [11]
15.0% Mean of Sylvester et al. [18] and Tolley 
et al. [11] values
MMC instillation cost 195.56 € Updated from Racioppi et al. [19]
TURB Costs
Base case 2,167.0 € Mean DRG value [21]
Sensitivity analysis 2,472.93 € Updated from Racioppi et al. [19]
Discount rate 2% Banca d’Italia yearly discount rate [16]
Table I. Parameters used in the cost-benefit analysis
MMC = mitomycin C; TURB = transurethral resection of bladder
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second and third year. Being so and conside-
ring that our reference population is compo-
sed of 12,500 patients who underwent TURB 
and that the cost of a single MMC instillation 
is 195.56 €, the NPV of costs becomes:
As mentioned above, benefits are those costs 
that are generated by patients that would ex-
perience a recurrence in case they have not 
been treated with MMC. These costs are 
those related to TURB performed on the per-
centage of patients that would not experience 
the recurrence when administered with post 
operative MMC, that are 1,462.5 (11.7% of 
12,500). As the cost of a TURB is 2,167.00 €, 
total benefits are 3,169,237.50 €.
Differently from costs, benefits are splitted 
during follow-up; El-Ghobashy et al. [22] 
found that 65% of the recurrences events in 
patients who underwent TURB alone were 
equally distribuited in the first two years fol-
low-up, while the remaining 35% were split-
ted during the remaining 20 months (median 
follow-up was of 44 months). To be conserva-
tive, we assumed that recurrences percentages 
were equal in each year of a 3 years follow-
up, raising benefits that are equally distribu-
ited during the 3 years too. Being so, every 
year, the amount of benefits is 1,055,356.09 €. 
While for the first year it is not necessary, for 
the second and the third year a discount rate 
must be applied in order to put all costs and 
benefits in the same time point to make them 
comparable. Using a 2% discount rate, total 
benefits for the second year are 1,034,662.83 
€, while they are of 1,014,765.47 € for the 
third year. Being so, NPV of benefits is:
Having costs and benefits NPVs, the NPV 
can be calculated as follows:
Analogously, the CBR is:
One-way sensitivity analysis 
on the recurrence rate 
reduction percentage
A sensitivity analysis has been done using 
the percentage of reduction in recurrence rate 
from Tolley et al. [11]; with a 19.2% reduction 
in recurrence rate, benefits raised by TURB 
avoided using MMC become 5,200,800.00 
€. As in the base case, it has been assumed 
that recurrences events are equally distribu-
ited during follow-up. Being so, and consi-
dering a discount rate of 2%, benefits NPV is 
5,095,030.79 €. Considering that costs NPV 
is the same of the base case scenario, NPV is 
now 2,650,530.79 € with a related CBR pare 
to 0.48.
Another sensitivity analysis on recurrence 
rate reduction has been done using a reduc-
tion percentage of 15%, that represents the 
mean value between the base case scenario 
and the best one described above. In this 
case, benefits raised by TURB avoided using 
MMC become 4,063,125.00 € and the related 
NPV and CBR are 1,535,992.80 € and 0.61 
respectively.
One-way sensitivity analysis 
on TURB costs
A last one-way sensitivity analysis has been 
done using TURB costs given by Racioppi et 
al. [19] instead of the mean cost associated to 
DRG 311 used in the base case scenario. The 
cost of TURB from Racioppi is 2,242.00 € in 
2006 hence the ISTAT coefficient has been 
applied raising a TURB cost of 2,472.93 € 
updated at 2011.
Being so, total benefits and total discounted 
benefits become 3,616,660.12 € and 
3,543,107.73 € respectively. The NPV is 
1,098,607.7 3€ with a related CBR pare to 
0.69.
DISCUSSION
Very few pharmacoeconomic analyses of 
NMIBC have been conducted worldwide and 
in particular in Italy.
Total costs (€) Costs NPV (€) Total benefits (€) Benefits NPV (€) NPV (€) CBR
Base case




19.2% 2,444,500.00 2,444,500.00 5,200,800.00 5,095,030.79 2,650,530.79 0.48
15 % 2,444,500.00 2,444,500.00 4,063,125.00 3,980,492.80 1,535,992.80 0.61
TURB costs
2,472.93 2,444,500.00 2,444,500.00 3,616,660.12 3,543,107.73 1,098,607.73 0.69
Table II. Results from Cost-Benefit analysis: base case and sensitivity analysis
CBR = cost-benefit ratio; NPV = Net Present Value
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In this cost-benefit analysis, the single imme-
diate post operative instillation of mitomycin 
C resulted to be cost-beneficial with a CBR 
that goes from 0.48 to 0.79 when compared to 
TURB alone raising a Net Present Value that 
goes from 660,284.39 € to 2,650,530.79€ and 
that represents the benefit derived from the 
expenditure the NHS will not incurs in.
As with any pharmacoeconomic analysis, 
there are some limitations. For example, bias 
may be present because of using data from 
different sources. In our case, the percentage 
of reduction in recurrence rates comes from 
a meta-analysis of 7 RCTs and from another 
RCT. The lack of data from observational 
studies is an important limitation to a phar-
macoeconomic study as analysis based mo-
stly on RCTs provide values that are far from 
“real life”. Another potential limitation of our 
study is that the analysis’ main clinical input 
was based on studies not performed in an Ita-
lian health care setting, but the probabilities 
of clinical events are not usually considered 
country specific [23]. Another important li-
mitation due to the lack of published local 
data, is that data on recurrences rate was not 
based on a study focused on mitomycin C 
only, but on instillations of related NMIBC 
chemotherapeutical drugs in general.
Even if a cost-benefit analysis has been per-
formed, no indirect costs have been men-
tioned since they are not relevant from the 
Italian National Health Service perspective 
and, in addition, low risk NMIBC difficultly 
incurs in this kind of costs as they are not in a 
life-threatening stage of disease.
CONCLUSION
The present study has demonstrated that even 
assuming conservative parameters for reduc-
tion in recurrence rates, adopting a single 
immediate post operative MMC instillation 
in low risk NMIBC patients would lower not 
only the recurrence rate but also the cost of 
caring for bladder cancer in Italy.
Having costs and benefits NPVs, the NPV 
can be calculated as follows:
Analogously, the CBR is:
One-way sensitivity analysis 
on the recurrence rate 
reduction percentage
A sensitivity analysis has been done using 
the percentage of reduction in recurrence rate 
from Tolley et al. [11]; with a 19.2% reduction 
in recurrence rate, benefits raised by TURB 
avoided using MMC become 5,200,800.00 
€. As in the base case, it has been assumed 
that recurrences events are equally distribu-
ited during follow-up. Being so, and consi-
dering a discount rate of 2%, benefits NPV is 
5,095,030.79 €. Considering that costs NPV 
is the same of the base case scenario, NPV is 
now 2,650,530.79 € with a related CBR pare 
to 0.48.
Another sensitivity analysis on recurrence 
rate reduction has been done using a reduc-
tion percentage of 15%, that represents the 
mean value between the base case scenario 
and the best one described above. In this 
case, benefits raised by TURB avoided using 
MMC become 4,063,125.00 € and the related 
NPV and CBR are 1,535,992.80 € and 0.61 
respectively.
One-way sensitivity analysis 
on TURB costs
A last one-way sensitivity analysis has been 
done using TURB costs given by Racioppi et 
al. [19] instead of the mean cost associated to 
DRG 311 used in the base case scenario. The 
cost of TURB from Racioppi is 2,242.00 € in 
2006 hence the ISTAT coefficient has been 
applied raising a TURB cost of 2,472.93 € 
updated at 2011.
Being so, total benefits and total discounted 
benefits become 3,616,660.12 € and 
3,543,107.73 € respectively. The NPV is 
1,098,607.7 3€ with a related CBR pare to 
0.69.
DISCUSSION
Very few pharmacoeconomic analyses of 
NMIBC have been conducted worldwide and 
in particular in Italy.
Total costs (€) Costs NPV (€) Total benefits (€) Benefits NPV (€) NPV (€) CBR
Base case




19.2% 2,444,500.00 2,444,500.00 5,200,800.00 5,095,030.79 2,650,530.79 0.48
15 % 2,444,500.00 2,444,500.00 4,063,125.00 3,980,492.80 1,535,992.80 0.61
TURB costs
2,472.93 2,444,500.00 2,444,500.00 3,616,660.12 3,543,107.73 1,098,607.73 0.69
Table II. Results from Cost-Benefit analysis: base case and sensitivity analysis
CBR = cost-benefit ratio; NPV = Net Present Value
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